| |
Low concentrations of the nucleotide HIV reverse transcriptase
inhibitor, tenofovir
Best BM, Letendre SL, Koopmans P, et al
J Acquir Immune Defic Syndr.
2012 Jan 3
Abstract
Abacavir, didanosine and tenofovir do not induce inflammatory,
apoptotic or oxidative stress genes in
coronary endothelial cells.
Kim C, Gupta SK, Green L,
et al
Antivir Ther.
2011;16(8):1335-9.
Abstract
Simultaneous Delivery of Tenofovir and Acyclovir via an Intravaginal
Ring.
Moss JA, Malone AM, Smith TJ, et al
Antimicrob Agents Chemother.
2011 Nov 28.
Abstract |
FULL-TEXT
ARTICLE
Enrollment Characteristics and Risk Behaviors of Injection Drug Users
Participating in the
Bangkok Tenofovir Study, Thailand.
Martin M, Vanichseni S,
Suntharasamai P. et al
PLoS One.
2011;6(9):e25127
Paper
The HIV reverse transcriptase inhibitor tenofovir induces cell cycle
arrest in human |
cancer cells.
Brüning A, Burger P, Gingelmaier A, Mylonas I.
Invest New Drugs.
2011 Jun 29.
Abstract
Low-density lipoprotein size and lipoprotein-associated
phospholipase A2 in HIV-infected patients
switching to abacavir or tenofovir.
Saumoy M, Ordoñez-Llanos J, Martínez E,
et al
Antivir Ther.
2011;16(4):459-468.
Abstract
Tenofovir selectively regulates production of inflammatory cytokines and shifts
the IL-12 / IL-10 balance
in human primary cells
Melchjorsen J, Risør MW, Søgaard OS,
et al
J Acquir Immune Defic Syndr. 2011 Apr 5
Abstract
Formulation of tenofovir-loaded functionalized solid lipid
nanoparticles intended for HIV prevention.
Alukda D, Sturgis T, Youan BB.
J Pharm Sci. 2011 Mar
15.
Abstract
Bioequivalence study of two oral tablet formulations containing
tenofovir disoproxil
fumarate in healthy volunteers.
Yerino GA, Halabe EK,
Zini E, Feleder EC.
Arzneimittelforschung.
2011;61(1):55-60.
Abstract
The Exploitation of "Exploitation" in the Tenofovir Prep Trial in Cameroon:
Lessons Learned from Media Coverage of an HIV Prevention Trial.
Mack N, Robinson ET, Macqueen KM, et al
J Empir Res Hum Res Ethics. 2010
Jun;5(2):3-19
Abstract |
|
Tenofovir for the treatment of hepatitis B virus.
Jenh AM, Thio CL, Pham PA.
Pharmacotherapy. 2009 Oct;29(10):1212-27.
Abstract |
Anti-hepatitis B virus activity in vitro of combinations of
tenofovir with nucleoside/nucleotide
analogues.
Zhu Y, Curtis M, Qi X, et al.
Antivir Chem Chemother.
2009;19(4):165-76.
Abstract |
Glomerular filtration rates in HIV-infected patients treated with and
without tenofovir:
a prospective, observational study.
Guaraldi G, Roverato A, Giovanardi C, et al
J Antimicrob Chemother.
2008 Dec 17.
Abstract
|
Acceptability of tenofovir gel as a vaginal microbicide by US male
participants in a Phase I
clinical trial (HPTN 050).
Carballo-Diéguez A, Balán IC
AIDS Care. 2007 Sep;19(8):1026-31.
Abstract
|
Tenofovir: new indication. For first-line antiretroviral therapy: wait and
see.
[No authors listed]
Prescrire Int. 2004 Oct;13(73):180-2.
Abstract
|
Tenofovir disoproxil fumarate.
Gallant JE, Deresinski S.
Clin Infect Dis. 2003 Oct 1;37(7):944-50
Abstract
Tenofovir disoproxil fumarate.
Grim SA, Romanelli F .
Ann Pharmacother 2003 Jun;37(6):849-59
Abstract |
Tenofovir Main Page
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
